Bigul

Alembic Pharmaceuticals Ltd - 533573 - Specimen Of The Reminder Letter Dated 6Th May, 2021 Sent To The Relevant Shareholders For Whom The Dividend Remains Unpaid / Unclaimed For Seven Or More Consecutive Years And Whose Shares Are Liable To Be Transferred To The Investor Education And Protection Fund ('IEPF')

Pursuant to Regulation 30 of the Listing Regulations, 2015, we enclose herewith a specimen of the reminder letter dated 6th May, 2021 sent to the relevant shareholders for whom the dividend remains unpaid / unclaimed for seven or more consecutive years and whose shares are liable to be transferred to the Investor Education and Protection Fund ('IEPF') Authority as per Section 124(6) of the Companies Act, 2013 read with Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, as amended from time to time. We request you to kindly take the same on record.
07-05-2021

Earnings Call for Q4FY21 of Alembic Pharmaceuticals

Conference Call with Alembic Pharmaceuticals Management and Analysts on Q4FY21 Performance and Outlook. Listen to the full earnings transcript.
07-05-2021
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution USP, 2% and 0.5%. Please find enclosed herewith our press release. We request you to kindly take the same on record.
05-05-2021

Alembic Pharma falls 6% post March quarter results

Alembic Pharma Q4FY21 operational performance was marginally below estimates, largely due to lower traction in US and Domestic Formulation (DF) sales
05-05-2021
Bigul

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

With reference to the captioned subject, this is to inform the exchange that the Company's joint venture, Aleor Dermaceuticals Limited, has received US Food and Drug Administration (USFDA) Tentative Approval for Metronidazole Gel USP, 1%. Please find enclosed herewith our press release. We request you to kindly take the same on record.
04-05-2021
Bigul

Alembic Pharmaceuticals Ltd - 533573 - Outcome Of Board Meeting

Please find attached herewith covering letter along with the documents.
04-05-2021
Bigul

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Acquisition

This is to inform you that the Company has subscribed to partnership interest in ABCD Technologies LLP (to be renamed as IndoHealth Services LLP). The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Clause A(1) of Part A, Schedule III of the aforesaid regulations, is attached as per 'Annexure A'. This is for your information and dissemination.
30-04-2021
Next Page
Close

Let's Open Free Demat Account